Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.61 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MB | P02144 | 1/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cp1-1189 SCHEMBL7379007 | 0.95 | CACNA1B (0.56) | CACNA1BAPBA1NR1H4EPHX2L3MBTL1 | |
| SCHEMBL17865779 | 0.84 | LMNA (0.58) | SMN1; SMN2HTTMAPTLMNAPOLB | |
| SCHEMBL22099992 | 0.84 | KIF11 (0.57) | SMN1; SMN2ALDH1A1MAPTLMNAMEN1 | |
| SCHEMBL20992041 | 0.84 | L3MBTL1 (0.68) | L3MBTL1SMN1; SMN2HTTALDH1A1MAPT | |
| SCHEMBL1176804 | 0.84 | USP2 (0.48) | NR1H4EPHX2SMN1; SMN2HTTMAPT | |
| SCHEMBL5506262 | 0.83 | NAMPT (0.60) | CACNA1BAPBA1NR1H4EPHX2L3MBTL1 | |
| SCHEMBL23139020 | 0.82 | NPC1 (0.55) | CACNA1BAPBA1NR1H4SMN1; SMN2MAPT | |
| SCHEMBL21282783 | 0.82 | HDAC3 (0.73) | NR1H4SMN1; SMN2MAPTLMNAMEN1 | |
| SCHEMBL15946358 | 0.82 | CACNA1B (0.67) | CACNA1BAPBA1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL13210697 | 0.82 | CACNA1B (0.85) | CACNA1BAPBA1NR1H4L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | claimed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | claimed |
| EP-3553169-B1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2021-11-03 | — | — | EP | claimed |
| US-20160331736-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2016-11-17 | — | — | US | claimed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | claimed |
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | claimed |
| US-20060100289-A1 | Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain | RENOVIS, INC. | 2006-05-11 | — | — | US | claimed |
| US-20060100461-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2006-05-11 | — | — | US | claimed |
| US-7005546-B2 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. (US) | 2006-02-28 | — | — | US | claimed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | claimed |
| EP-1332363-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2003-08-06 | — | — | EP | claimed |
| US-6509378-B2 | Parkinson's disease; ability to antagonize MPTP induced reduction in dopamine levels; amidation of the nitrobenzoyl halide with alkylamine | CENTAUR PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | claimed |
| WO-2002031499-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2002-04-18 | — | — | WO | claimed |
| US-20010037040-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2001-11-01 | — | — | US | claimed |
| EP-0819113-B1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS INC (US) | 2001-06-27 | — | — | EP | claimed |
| US-6194465-B1 | ADMINISTERING ACETAMIDO-, NITRO-, OR AMINO-MONO- OR DISUBSTITUTED N-ALKYL BENZAMIDE COMPOUNDS SUCH AS N-TERT-BUTYL-4-ACETAMIDOBENZAMIDE FOR PROPHLAXIS OR TREATMENT OF AN INFLAMMATORY BOWEL CONDITION IN A PATIENT | CENTAUR PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | claimed |
| EP-0912171-A1 | BENZAMIDE TREATMENT OF DEMENTIA ASSOCIATED WITH AIDS VIRUS (HIV-1) INFECTION | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | EP | claimed |
| US-5756548-A | TREATMENT OF PARKINSON*S DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1998-05-26 | — | — | US | claimed |
| WO-1997038684-A1 | BENZAMIDE TREATMENT OF DEMENTIA ASSOCIATED WITH AIDS VIRUS (HIV-1) INFECTION | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-10-23 | — | — | WO | claimed |
| US-5658953-A | Pharmaceutical compositions of acetamidobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100289-A1 | Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain | MMP8, PTGES, NGF | CACNA1B 946/4885APBA1 1401/4885NR1H4 1670/4885 |
| US-20010037040-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | CACNA1B 1087/4885APBA1 29/4885NR1H4 4248/4885 |
| US-20060100461-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | CACNA1B 1087/4885APBA1 29/4885NR1H4 4248/4885 |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | CACNA1B 2643/4885APBA1 3447/4885NR1H4 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.